2021. Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study. Clinics. 76, (Nov. 2021), e2251. DOI:https://doi.org/10.6061/clinics/2021/e2251.